INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab
Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia The study did not meet the primary efficacy endpoint Study confirms the safety profile of …